Abstract:
Cardiorenal syndrome (CRS) is a condition in which acute or chronic dysfunction of one organ of the heart or kidney results in acute or chronic dysfunction of the other organ. Although the diagnosis and treatment of CRS are increasingly understood, there are no specific biomarkers for the early diagnosis and treatment of CRS. In recent years, a large number of studies have shown that Galectin-3 (Gal-3) can be used as a novel biomarker in heart and kidney diseases,to provide a new way of diagnosis and treatment of CRS.